Not yet recruitingObservationalLast updated Aug 10, 2026

Pharmacokinetic Study of Therapeutic Plasma Exchange

A Phase 1 Pharmacokinetic Study of Therapeutic Plasma Exchange for Severe Immune-Related Adverse Events From Immune Checkpoint Inhibitors

Overview

ClinicalTrials.gov ID: NCT07756242
Lead Sponsor: University of ChicagoOTHER
Brief Summary: The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.
Study Type: Observational

Status

Study Record Dates

NCT05004493Recruiting

Biorepository and Registry for Plasma Exchange Patients

NCT01210716Completed

Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device

NCT07100990Recruiting

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

NCT05414552Completed

ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment

NCT05700565Recruiting

Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype

NCT06534450Unknown status

The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics